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  Requirements for Registration of Pharmaceuticals for Human  
 Use  
IMDM   Iscove's Modified Dulbecco's Medium 
K562    Human chronic myelogenous leukemia cell line  
                                    (ATCC No. CCL-243) 
KCl    Potassium chloride 
LC50    Lethal concentration at 50% viability 
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M    Molar 
MDR   Multidrug resistance 
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Mg    Magnesium 
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MK-2    Mitogen activated protein kinase-activated protein kinase 2 
mL    Millilitres 
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MRP1   Multidrug resistance-associated protein 1 
MS    Mass spectrometry 
MTT    3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
N    Necrosis 
N    Nitrogen 
NADH   Nicotinamide adenine dinucleotide hydrate 
NADP   Nicotinamide adenine dinucleotide phosphate  
NADPH   Nicotinamide adenine dinucleotide phosphate hydrate 
NaH    Sodium hydride 
NCI                National Cancer Institute  
ND                   Not determined 
NF    Nitrofluorene 
NG    Normal growing 
NHEJ    Non-homologous end-joining 
nm    Nanometre 
NMR    Nuclear magnetic resonance 
NTP    National Toxicology Program 
O   Oxygen  
OECD       Organisation for Economic Co-operation and Development 
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*P    Significant difference at P-value of less than 0.05 
**P   Significant difference at P-value of less than 0.01 
***P   Significant difference at P-value of less than 0.001 
PARP-1  Poly (ADP-ribose) polymerase-1 
PBS   Phosphate buffer saline  
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PLK1                Polo-like kinase 1  
PI                       Propidium iodide 
RCC                  Relative cell count 
REACH            Registration, Evaluation, Authorisation and Restriction of 
Chemicals 
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RFU                   Relative Fluorescence Unit 
RICC                   Relative increase in cell counts 
RLU                    Relative Luminescence Unit 
RNA                   Ribonucleic acid 
RNase                 Ribonuclease 
RO5    Lipinski‘s rule of five 
RPD                    Relative population doubling 
rpm                       Revolutions per minute 
RS                        Relative survival 
S                           Sulphur 
S9                        Post mitochondrial fraction prepared from the livers of rodents 
SAR   Structure activity relationship 
SD                       Standard deviation 
SEM   Standard error of the mean 
SG                       Slow growing 
SHE                    Syrian hamster embryo 
SI                          Selectivity index 
SMAC                 Second mitochondria-derived activator of caspases 
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T0                        Optical density at time zero 
tAIF        Truncated apoptosis inducing factor 
tBID    Truncated BH3 interacting-domain death agonist 
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TK gene   Thymidine kinase gene 
TK6    Human lymphoblast cell line (ATCC No. CRL-8015) 
TKI   Tyrosine kinase inhibitor 
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TNF    Tumour necrosis factor 
TNFR1  Tumour necrosis factor receptor 1 protein 
TRADD   TNFR1-associated death domain protein 
Trypsin-EDTA  0.25% Trypsin - 0.02% EDTA  
TW    Total wells 
μg/mL   Microgram per millilitre 
µL    Microlitre 
µM    Micromolar 
V    Viable 
v/v    Volume per volume  
WHO    World Health Organization 
w/v    Weight per volume 
XIAP    X-linked inhibitor of apoptosis protein 
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APOPTOSIS DAN GENOTOKSIK BAGI SEBATIAN β-KARBOLINA 
TERHADAP LEUKEMIA MIELOGENUS KRONIK  
DENGAN MENGGUNAKAN MODEL EKSPERIMEN IN VITRO 
 
ABSTRAK 
β-karbolina dikenali dengan banyak kegunaan tradisional, dan telah diselidik 
secara meluas untuk pelbagai indikasi kesihatan. Khususnya, baru-baru ini β-karbolina 
telah menunjukkan beberapa penemuan yang memberangsangkan dalam bidang 
antikanser. Maka kajian ini menyelidiki potensi sebatian β-karbolina bagi aktiviti 
antikanser menggunakan kaedah model in vitro. Tiga puluh sebatian β-karbolina yang 
disintesis telah diuji menggunakan asai 3-(4,5-Dimetilthiazol-2-yl)-2,5-
difeniltetrazolium bromida (MTT) untuk aktiviti antikanser dan indeks selektiviti (SI) 
terhadap empat jenis sel kanser manusia (kolon HT-29, serviks HeLa, hati Hep G2 dan 
leukemia K562) dan dua jenis sel bukan kanser (fibroblas embrio tikus BALB/c3T3 dan 
fibroblas kulit khatan manusia Hs27). Berdasarkan selektiviti yang tertinggi, tujuh 
sebatian telah dipilih untuk sel leukemia mielogenus kronik (CML) K562. Beberapa 
eksperimen telah dilakukan untuk memahami ciri-ciri sebatian tersebut dan menyelidik 
mekanisme tindakan separa bagi sel K562. Keputusan daripada asai MTT 
mencadangkan sebatian yang terpilih boleh menghasilkan aktiviti menghalang 
pertumbuhan sel secara maksima (IC100) dari kepekatan 9.1 μM hingga 56.9 μM dalam 
48 jam.  Selain itu, sebatian tersebut bertindak sebagai agen sitostatik dan sitosidal 
apabila digunakan masing-masing pada kepekatan yang rendah dan tinggi. Kajian 
mekanisme tindakan separa menerusi pewarnaan flouresens akridina jingga dan etidium 
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bromida (AO/EB) dan asai luminesens kaspase-3 dan -7  telah menunjukkan yang 
sebatian terpilih mencetus apoptosis terhadap sel K562 tanpa peningkatan tahap kaspase, 
maka boleh menyimpulkan bahawa apoptosis bukan klasik bebas kaspase adalah 
bertanggungjawab. Sebagai tambahan, analisis kitaran sel menerusi aliran sitometri 
menunjukkan gangguan pada peringkat awal disebabkan pemberhentian pertumbuhan 
sel pada fasa G0/G1. Kajian keselamatan dalam bentuk genotoksik dikaji dengan 
selanjutnya menggunakan beberapa ujian genotoksik dengan dan tanpa kehadiran fraksi 
S9 dari hati tikus untuk pengaktifan metabolism. Ujian Ames bakteria Salmonella 
typhimurium dan ujian gen timidina kinase (TK) sel mamalia telah dijalankan untuk 
menyelidiki mutagenisiti, manakala ujian mikronukleus (MN) dan asai sel transformasi 
(CTA) yang bebas tambatan telah dijalankan untuk menyelidiki genotoksik dan 
karsinogenik masing-masing. Eksperimen-eksperimen in vitro ini telah membuktikan 
yang sebatian tersebut tidak genotoksik, tidak mutagenik dan tidak karsinogenik. Maka 
boleh dicadangkan bahawa ketujuh-tujuh sebatian β-karbolina telah menunjukkan 
potensi yang baik untuk dikembangkan pada masa hadapan sebagai agen antikanser, 
khususnya terhadap CML, berdasarkan potensi, selektiviti dan keselamatan in vitro. 
 
 
 
 
 
xxv 
 
APOPTOSIS AND GENOTOXICITY OF SELECTED β-CARBOLINE 
COMPOUNDS AGAINST CHRONIC MYELOGENOUS LEUKEMIA  
USING IN VITRO EXPERIMENTAL MODELS 
 
ABSTRACT 
β-carboline is known for its numerous traditional uses and has been widely 
investigated for various health indications. In particular, recently β-carboline has shown 
some promising findings in the field of anticancer.  Hence this study investigates the 
potential anticancer activity of β-carboline compounds using in vitro models. Thirty 
synthesized β-carboline compounds were tested using 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay for anticancer activity and selectivity index 
(SI) against four human cancer (colon HT-29, cervical HeLa, liver Hep G2 and leukemia 
K562) and two non-cancer (mouse embryo fibroblasts BALB/c3T3 and human foreskin 
fibroblasts Hs27) cell lines. Based on the highest selectivity, seven compounds were 
selected for K562 chronic myelogenous leukemia (CML) cells. A series of experiments 
were further performed to understand the characteristics of the compounds as well as to 
investigate their partial mechanism of action in K562 cells. Results from MTT assay 
have indicated that the selected compounds were able to induce maximal inhibitory 
activity (IC100) at a range of concentrations from 9.1 µM to 56.9 µM at 48 hours. 
Furthermore, the compounds acted both as cytostatic and cytocidal agents, when treated 
at low and high concentrations respectively. Partial mechanism of action studies by 
acridine orange and ethidium bromide (AO/EB) fluorescence staining and caspase-3 and 
-7 luminescence assay have shown that the selected compounds induced apoptosis in 
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K562 cells with no upregulation of the caspases, and therefore it could be deduced that 
non-classical caspase-independent apoptosis was responsible. In addition, cell cycle 
analysis by flow cytometry showed disruption at the initial stage due to cell arrest at 
G0/G1 phases. Safety studies in the form of genotoxicity were further evaluated using a 
battery of genotoxicity tests in the presence and in the absence of rat liver S9 metabolic 
activation. Salmonella typhimurium bacteria Ames test and mammalian cell thymidine 
kinase (TK) gene test were conducted for mutagenicity investigation, while 
micronucleus (MN) test and anchorage-independent cell transformation assay (CTA) 
were performed for genotoxicity and carcinogenicity investigations respectively. These 
in vitro experiments have proven that the compounds were non-genotoxic, non-
mutagenic and non-carcinogenic. Hence, it could be postulated that these seven 
compounds of β-carboline have shown good potential to be developed in the future as 
antileukemic agents, specifically against CML, due to their in vitro potency, selectivity 
and safety.  
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CHAPTER 1 
 
1.0 INTRODUCTION 
 
1.1 Anticancer 
  
1.1.1 Definition of cancer 
 
Cancer is characterized by abnormal, excessive, uncoordinated, and autonomous 
proliferation of cells, even after the cessation of stimulus for growth which caused it 
(Yadav and Nandi, 2014). Cancer is thought to result from the accumulation of multiple 
genetic aberrations that transform normal cells into cancer cells (Cheon and Orsulic, 
2011).  
 
1.1.2 Cancer statistics 
 
Cancer is now one of the leading causes of morbidity and mortality worldwide. World 
Health Organization (WHO), through its cancer research agency, International Agency 
for Research on Cancer (IARC) has conducted GLOBOCAN project, which aimed to 
provide contemporary estimates of the incidence of mortality and prevalence from major 
types of cancer for 184 countries of the world based on 2012 data. The project found that 
an estimated 14.1 million new cancer cases occurred around the world and this 
staggering number is expected to increase to 24 million by 2035. In addition, an 
estimation of 8.2 million cancer deaths have occurred and 32.6 million people were 
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living with cancer (within 5 years of diagnosis) in 2012 worldwide (Ferlay et al., 2014). 
With the increase of human life expectancy, so is the incidence of malignant tumors 
which increases at speed 1.5 to 2.0% every 10 years (Hunold et al., 2006).  
 
In Malaysia, based on 2015 record from the Ministry of Health, cancer which 
contributed to 13.56% of all deaths, was the third most common cause of death after 
diseases of circulatory system (22.77%) and diseases of the respiratory system (18.54%), 
where it was also reported that during the period of 2007 to 2011, 103 507 deaths have 
occurred due to cancer (Azizah et al., 2015). 
 
1.1.3 Hallmarks of cancer 
 
Cancer is a complex disease which operates in multiple ways. Hallmarks of cancer 
include at least a few of the characteristics as depicted in Figure 1.1 (Hanahan and 
Weinberg, 2011). 
 
1.1.4 Chemotherapy drugs  
 
Many forms of chemotherapy are targeted at the process of cell division. The rationale 
being that cancer cells are more likely to be replicating than normal cells. Chemotherapy 
drugs include a number of families defined by both their chemical structures and 
mechanisms of action: alkylating agents, antimetabolites, cytotoxic antibiotics, 
topoisomerase inhibitors, spindle poisons and platinum compounds (Espinosa et al., 
2003; Payne and Miles, 2008). Other more advanced cancer treatments include targeted 
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therapy, hormone therapy, immunotherapy, stem cell transplant and precision medicine 
(National Cancer Institute, 2017).  
 
 
 
Figure 1.1. Hallmarks of cancer (Source: Hanahan and Weinberg, 2011). 
 
At present, chemotherapeutics are the main source of treatments in the 
management of cancer. Even with the arrival of targeted-therapy revolution, the 
principles and limitations of chemotherapy discovered by the early researchers still 
apply till today (Chabner and Roberts, 2005). The primary reasons for treatment failure 
in cancer chemotherapy are the infamous severe side effects to the normal cells and the 
ever-increasing emergence of the multidrug resistance of cancer cells to chemotherapy 
(Harleva et al., 2012; Leite de Oliveira et al., 2012; Holohan et al., 2013). 
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1.1.5 Leukemia 
 
Leukemia is a cancer of the blood, specifically the white blood cells, and is common 
among both adults and children (Wiseman, 2008; Siegel et al., 2012; Teichroew, 2016). 
Leukemia incidence rates have been rising on average 0.3% each year over the last 10 
years, though death rates have been falling on average 1.0% each year over 2005 to 2014 
(National Cancer Institute, 2016). It is one of the most common cancers worldwide, and 
it is also number one in causing childhood cancer, by up to 34% of all types of cancer in 
children (Wiseman, 2008; Siegel et al., 2012). Among the Malaysian population, 
leukemia is the sixth most common cancer in adults as well as the number one most 
common cancer among children (Azizah et al., 2015).  
 
There are four primary types of leukemia which are categorized based on their 
rates of progression and where the cancer develops; acute myeloid (or myelogenous) 
leukemia (AML), chronic myeloid (or myelogenous) leukemia (CML), acute 
lymphocytic (or lymphoblastic) leukemia (ALL) and chronic lymphocytic leukemia 
(CLL) (American Cancer Society, 2017; Teichroew, 2016). In this study particularly, 
leukemia of interest is CML, which was represented by K562 cell line. 
 
1.1.6 Chronic myelogenous leukemia (CML) 
 
Compared to other types of leukemia, CML is most commonly diagnosed among adults 
with an incidence rate of 1-1.5 per 100 000 people, and represents approximately 15% of 
all leukemias with onset age at 40–60 years. On the other hand, children and adolescents 
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make up 3% of diagnosed cases (Ries et al., 1999; Jabbour and Kantarjian, 2012; 
American Cancer Society, 2017a). This malignant hematopoietic disorder which is 
characterized by uninhibited proliferation of abnormal and undifferentiated blood 
progenitor/stem cells (specifically myeloid cells), also known as blast cells (Druker et 
al., 2001; Kalidas et al., 2001), begins its attack in the blood-forming cells of the bone 
marrow. With time progression, the malignancy starts spreading to the blood and 
eventually circulating to other areas of the body. When blood and bone marrow are 
overflowed with these blast cells, healthy white blood cells, red blood cells, and platelets 
which usually occupy these sites have no space to proliferate. Many clinical side effects 
are expressed as a result of this anomaly, in the form of infections, anemia, ease of 
bleeding, pain in the bones and pain or fullness feeling below the ribs on the left side 
(Abou-Jawde et al., 2003; Moosavi et al., 2006; PDQ® Adult Treatment Editorial 
Board, 2017). 
 
CML spreads and progresses slowly and it has three distinct phases; chronic, 
accelerated and blastic (Abou-Jawde et al., 2003; Moosavi et al., 2006; PDQ® Adult 
Treatment Editorial Board, 2017). These phases are determined based on two factors, 
which are how many blast cells are there in the blood and bone marrow and how severe 
the signs or symptoms are (PDQ® Adult Treatment Editorial Board, 2017). Chronic 
phase is characterized as having less than 10% of blast cells in the blood and bone 
marrow. Most CML patients are diagnosed in this phase, and disease outcome is 
generally easily manageable with outpatient therapy. Given approximately 3-8 years, 
disease progression goes to the next phase which is the accelerated phase, or straight to 
the blastic phase (Lee, 2000; Axdorph et al., 2002).  In the accelerated phase, the blood 
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and bone marrow contain between 10-19% of blast cells, and early signs of symptoms 
start to appear. Further progression is to the blastic phase, where at this time, the blood 
and bone marrow contain 20% or more of blast cells. This phase is also called blast 
crisis, where symptoms such as tiredness, fever, and enlarged spleen begin to appear and 
the transformation may be associated with a markedly deteriorated prognosis (Lee, 
2000; Axdorph et al., 2002; PDQ® Adult Treatment Editorial Board, 2017).  
 
1.1.6(a) Pathogenesis of chronic myelogenous leukemia (CML) 
 
CML has a distinct characteristic that makes it different from the other three leukemias. 
This distinction comes from CML‘s association with an abnormal chromosome known 
as the Philadelphia chromosome (Figure 1.2), which arises from the reciprocal 
translocation of genes between two chromosomes, whereby a piece of chromosome 9 
(ABL) and a piece of chromosome 22 (BCR) break off and exchange places in 
pluripotent hematopoietic stem cells. Formation of this new BCR-ABL gene is on 
chromosome 22 where the piece from chromosome 9 attaches, and the changed 
chromosome 22 is now called the Philadelphia chromosome (Deininger et al., 2000; 
O‘Dwyer, 2002; PDQ® Adult Treatment Editorial Board, 2017). The BCR-ABL 
oncogene encodes a fusion protein p210 BCR-ABL with deregulated tyrosine kinase, 
which is responsible for cell growth independent of growth factor, survival of myeloid 
progenitor cells, apoptotic resistance, arrested lymphoid development and multistep 
oncogenic progression, thus responsible for leukemogenesis (Deininger et al., 2000; 
O‘Dwyer, 2002; Abou-Jawde et al., 2003). The discovery and widespread prescription 
of BCR-ABL tyrosine kinase inhibitors has benefited CML patients due to an increase in 
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the 5-year survival rate of 55.2% for diagnosed patients from 2001 to 2007, in 
comparison to back in 1990 to 1992, when their 5-year survival rate was only 31.0% 
(Siegel et al., 2012).  
 
 
Figure 1.2. Translocation process of fusion product, BCR-ABL oncogene, also known as 
Philadelphia chromosome between chromosomes 9 and 22 (Source: PDQ® Adult 
Treatment Editorial Board, 2017).  
 
1.1.6(b) Failed strategy to target BCR-ABL gene 
 
The pathogenesis of CML which is derived from the formation of BCR-ABL 
gene constitutes an attractive target for antisense strategies. The principle of antisense 
strategies relies on the formation of duplex complexes between the target mRNA and 
exogenous antisense oligonucleotide (short DNA or RNA nucleotides), therefore 
preventing the action of ribosomal complex to read and translate the transcribed message 
(Gewirtz et al.,1998; Galderisi et al., 1999; Salesse and Verfaillie, 2002). Unfortunately, 
such strategies failed to deliver due to some technical problems. The long half-life of 
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p210 BCR-ABL (> 24 hours) required extended ex vivo culture to induce leukemic cell 
death and such would interfere with the engraftment ability of hematopoietic progenitors 
(Spiller et al., 1998; Spiller et al., 1998a; Clark, 2000; Salesse and Verfaillie, 2002). In 
addition, there has been evidence showing that the mRNA and protein of BCR-ABL 
gene were not expressed in CML stem cells, so treatment with antisense oligonucleotide 
failed to eliminate the leukemic cells (Salesse and Verfaillie, 2002). Therefore, in an 
effort to target the BCR-ABL gene effectively, drug inhibitors of the BCR-ABL fusion 
protein were developed, known as tyrosine kinase inhibitor (TKI) (Druker et al., 2003).  
 
1.1.6(c) Imatinib 
 
The most common drug for CML is imatinib, a moderately potent inhibitor of the 
kinase BCR–ABL, whose action is to inhibit tyrosine phosphorylation of proteins 
involved in BCR-ABL signal transduction by competitively inhibiting the adenosine 
triphosphate binding site of the tyrosine kinase enzyme. As a result of such mechanism 
of action, growth arrest or even apoptosis caused by imatinib occurs on BCR-ABL gene 
expressed hematopoietic cells without inflicting the normal cells (Druker et al., 2003). 
Patients with chronic-phase CML benefit from this drug, whereby about 80-90% would 
achieve complete haematological remission and many would lose cytogenetic evidence 
of the malignant clone (Chabner and Roberts, 2005; Radich, 2007). However, the 
progression of CML affects the effectiveness of imatinib therapy. For accelerated phase, 
the complete cytogenetic response rate reduced to 40%, and this number reduced further 
to only 20% for patients in the blast crisis. The reason for such profile might stem from 
9 
 
the fact that cells are more exposed to genomic instability as a result of longer activation 
of BCR-ABL prior to initiation of therapy (Radich, 2007).  
 
1.1.6(c)(i) Problems with imatinib treatment 
 
The use of imatinib has been shown to induce mild to moderate toxicity, though adverse 
effects could occur within the two years of the start of therapy. Just like any other 
chemotherapy drugs, imatinib comes with a few side effects such as nausea, lethargy, 
edema, myalgias, diarrhea and myelosuppression (Druker et al., 2003). Some patients 
also suffer through conditions of rashes‘ development, debilitating bone pain, 
oligospermia, gynecomastia and on some occasions, hepatotoxicity and cardiotoxicity 
(Grey et al., 2006; Seymour et al., 2006; Mughal and Schrieber, 2010).  
 
In spite of the side effects, the major issue with imatinib treatment for CML is 
the development of resistance, whereby up till now, approximately 100 different BCR–
ABL kinase domain mutations have been reported (Ernst and Hochhaus, 2012). The 
failure of the TKI to effectively eradicate leukemic cells could be attributed to an 
increase in efflux transport through the activation of various drug efflux transmembrane 
proteins in the forms of adenosine triphosphate (ATP)-binding-cassette (ABC) 
transporter family P-glycoprotein (Pgp), multidrug resistance-associated protein 1 
(MRP1) and breast cancer resistance protein (BCRP) (Chen and Sikic, 2012). Other 
mechanisms of resistance include decrease in influx transport (White et al., 2006) as 
well as increased resistance to apoptosis due to loss or mutation of apoptotic components 
such as p53 and members of the B-cell lymphoma 2 (BCL-2) family (regulation of the 
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intrinsic pathway) and extrinsic death receptor pathway (Honda et al., 2000; Selleri and 
Maciejewski, 2000; Aichberger et al., 2005; Gonzalez et al., 2010).  
 
In an effort to overcome this resistance problem, second generation of selective 
BCR–ABL TKIs such as nilotinib and dasatinib have been developed (Talpaz et al., 
2006; Kantarjian et al., 2007). Unfortunately for a minority of CML patients in the 
chronic phase as well as some substantial proportion in the advanced phases, they are 
either initially refractory or eventually develop resistance to these drugs (Ernst and 
Hochhaus, 2012).   
 
Even after treatment and supposed remission, the advanced technology of 
polymerase chain reaction (PCR) analysis can still detect BCR–ABL oncogene in cells 
of most patients (Druker et al., 2001; Kantarjian et al., 2002; Hughes et al., 2003). These 
mutational abnormalities cause the enzyme to stay in its open configuration, leading to 
poor binding of the drug but remaining catalytically active (Shah et al., 2002). 
Moreover, there is evidence that drug-resistant cells are present even before drug 
exposure for some of these patients with chronic phase CML, (Roche-Lestienne et al., 
2002), a finding which is usually associated with rapid emergence of resistance 
(Branford et al., 2003).  In the blast phase of CML, imatinib can only induce short 
remissions as the treatment introduces rapid outgrowth of cells which are mutated and 
drug resistant (Chabner and Roberts, 2005).  
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In this study, in vitro investigation of CML was represented through the use of 
K562 cell line. Other cell lines were also utilized to represent other types of cancer, 
namely HT-29 for colon cancer, HeLa for cervical cancer and Hep G2 for liver cancer. 
However, this study emphasized on K562 cell line as the β-carboline compounds have 
shown highest potency and selectivity to this particular cell line (sections 3.1.1 and 
3.1.2), in comparison to the other three cell lines.  
 
 
1.1.7 K562 cell line 
 
K562 is an erythroblastic cell line which has been established from the pleural 
extravasation of a patient with CML in blast crisis and behaves as a pluripotent 
hematopoietic stem cell (Klein et al., 1976). It expresses the typical pathogenic hallmark 
of human CML which is the fusion protein product of a chromosomal translocation 
Philadelphia chromosome (BCR-ABL oncogene) (Lozzio and Lozzio, 1975; Law et al., 
1993; Deininger et al., 2000; O‘Dwyer, 2002; Pastwa et al., 2005). In addition, K562 
cells also have mutated p53 gene, which is a tumor suppressor gene required for the 
induction of programmed cell death initiated by DNA damage (Lozzio and Lozzio, 
1975; Moosavi et al., 2006). This cell line has been extensively used as a suitable and 
worldwide model for in vitro investigation of CML and to probe into the metabolic 
pathways underlying its therapy (Law et al., 1993). K562 cell line has been also utilized 
in in vitro experimental system for the study of differentiation potential of many 
compounds (Klein et al., 1976; Law et al., 1993; Clarkson et al., 2003). Perhaps due to 
the combination of the p53 mutation and BCR-ABL oncogene expression, the K562 cell 
line displayed a relatively high level of resistance to most cytotoxic drugs, hence it has 
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been the object of experiments to test resistance in apoptosis-inducing drugs (Martin et 
al., 1990; McGahon et al., 1994; Dubrez et al., 1998).  
 
1.1.8 β-carboline 
 
β-carboline can be derived from a large group of naturally occurring and synthetic 
alkaloids. The general scaffold is characterized by a planar tricyclic system, which 
consists of pyridine ring that is fused to an indole skeleton, as shown in Figure 1.3 
(Love, 2006; Cao et al., 2007).  
 
 
 
Figure 1.3. General scaffold of β-carboline depicting a planar tricyclic system. 
 
1.1.8(a) Origins 
 
β-carboline is structurally related to harmine, an active alkaloid originally isolated from 
a plant called Peganum harmala L. family Zygophyllaceae (also known as harmal, 
harmel, Syrian rue, espand, etc.) (Kuo et al., 2003; Herraiz et al., 2010). Other major 
active components of Peganum harmala‘s extracts are identified to be harmol, 
harmaline, harmalol and harman, which are all β‑carboline alkaloids (Lamchouri et al. 
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1999; Herraiz et al., 2010). Peganum harmala is a perennial herbaceous plant native and 
widely used as a medicinal plant in Iran, Central Asia, North Africa, Middle East, 
Mediterranean Sea, Pakistan and India, where it was later introduced and naturalized in 
parts of the southwest USA, and a few areas of South Africa and Australia (Sheahan and 
Chase, 2000; Frison et al., 2009; El Gendy and El-Kadi, 2009; Herraiz et al., 2010; 
Wanntorp and Ronse De Craene, 2011). 
 
1.1.8(b) Traditional uses 
 
Since ancient times, β-carboline has been known for a plethora of traditional uses. Some 
of the treatments of β-carboline are for hypertension, cardiac diseases, diabetes 
(Tahraoui et al., 2007; Bnouham et al., 2002), depression (Brobst et al., 2009), 
antipyretic (Farouk et al., 2008), antispasmodic, emetic (Prashanth and John, 1999), 
hallucinogenic, antibacterial (Sokmen et al., 1999), antimalarial (Chen et al., 2004), pain 
relief, diarrhea, intestinal pain, asthma (Farouk et al., 2008), alimentary tract cancers 
(Chen et al., 2004), emmenagogue and abortifacient (Monsef et al., 2004). More known 
traditional uses of β-carboline are listed in a review by Moloudizargari et al. (2013). 
 
1.1.8(c) Pharmacological effects 
 
β-carboline has a wide spectrum of action especially on muscular, cardiovascular and 
central nervous systems (Aqel and Hadidi, 1991; Farouk et al., 2008; Moura et al., 
2007). Hence its pharmacological effects are even more varied, as the ring system from 
β-carboline scaffold has been shown to be effective for many biological activities; 
14 
 
anticancer (Plassmann et al., 2005), antioxidant (Moura et al., 2007), antiinflammatory 
(Trudell et al., 1992), antidepressant (Castro et al., 2003), anticonvulsant, antidiabetic 
(Fortunato et al., 2009), antibacterial (Nenaah, 2010), antiviral, antiparasitic (Alomar et 
al., 2013; Cao et al., 2007), antiarrhythmic, antimicrobial (Saadabi, 2006; Savariz et al., 
2012), antispasmodic, anticholinergic (Aqel and Hadidi, 1991),  neuroprotection (Maher 
and Davis, 1996), analgesic (Farouk et al., 2008), sedative, anxiolytic (Schlecker et al., 
1995; Batch and Dodd, 1998) and treatment for erectile dysfunction (Ahmed et al., 
2012). More known pharmacological effects of β-carboline are listed in a review by 
Moloudizargari et al. (2013). 
 
1.1.8(d) Adverse effects  
 
Though not as widely reported as the pharmacological effects, there are some reports of 
the detrimental effects of β-carboline. There is strong evidence that β-carboline alkaloid 
is highly neurotoxic and causes tremor in a wide variety of animals (Du et al., 1997; 
Louis, 2008). This may also lead to the pathogenesis of Parkinson's disease (Polanski et 
al., 2010), as evidenced by significantly high plasma levels of norharmane and harmane 
(alkaloids of β-carboline) in Parkinsonian patients compared to the control group (Kuhn 
et al., 1995). Overdose ingestion of Peganum harmala for medicinal use or as a 
recreational psychoactive product can be poison and several cases of toxicity have been 
already reported in animals and humans as it has been found to produce paralysis, 
euphoria, convulsions, hallucinations, digestive problems (nausea, vomiting), 
hypothermia and bradycardia (Ben Salah et al., 1986; Elbahri and Chemli, 1991; Frison 
et al., 2009; Mahmoudian et al., 2002).   
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1.1.8(e) Anticancer activity of β-carboline 
 
The emergence of anticancer potential of β-carboline has attracted a lot of scientific 
attention. Some of the β-carboline extracts have shown significant tumor inhibition 
effect in tumor‑bearing mice and in vitro studies have also shown that β‑carbolines, such 
as harmine, are highly cytotoxic and significantly inhibit tumor cell growth through 
apoptosis (Ishida et al., 1999; Lamchouri et al., 1999; Uezono et al., 2001; Kuo et al., 
2003). In fact, some papers have reported that β-carboline elicited even better anticancer 
activities in a wide range of cancer cell lines in comparison to known anticancer drugs 
cisplatin, carboplatin and 5-fluorouracil (5-FU) (Al-Allaf and Rashan, 1998; Yoshino et 
al., 1999; Cao et al., 2013). In vivo studies using mice bearing cancer cells also showed 
better antitumor activity compared to anticancer drug cyclophosphamide (Cao et al., 
2013). Moreover, there are even more anticancer studies of β-carboline which have 
shown good killing activity against a broad range of human cancer cell lines such as 
K562, HT-29, HeLa, Hep G2, U251, MCF-7, UACC-62, PCO-3, OVCAR-03, NCI-460, 
Bel-7402, BGC-823, A549, SCaBER, Blu-87 and KB (Cao et al., 2004; Cao et al., 
2005; Shen et al., 2005; Formagio et al., 2008; Han et al., 2012; Savariz et al., 2012).   
 
1.1.8(f) Mechanisms of action of β-carboline 
 
Literature has reported that β-carboline compounds exhibit their anticancer activity 
through multiple mechanisms. They mediate their action mainly through DNA 
intercalation as well as inhibiting cyclin‑dependent kinases (CDKs) and DNA 
topoisomerases (Hayashi et al., 1977; Taira et al. 1997; Csányi et al., 2000; Deveau et 
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al., 2001; Xiao et al., 2001; Song et al., 2002; Nii, 2003; Song et al., 2004). Other 
reported targets include cytochrome P450, monoamine oxidase A, mitogen activated 
protein kinase-activated protein kinase 2 (MK-2), pololike kinase-1 (PLK1), IĸK (IĸB 
kinase complex), kinesin Eg5 and dual enzyme tyrosine phosphorylated and regulated 
kinase 1a (DYRK1A) as well as benzodiazepine, serotonin, dopamine and imidazoline 
receptors (Fernandez de Arriba et al., 1994; Pimpinella and Palmery, 1995; Funayama et 
al., 1996; Kim et al., 1997; Grella et al., 1998; Stawowy et al., 1999; Glennon et al., 
2000; Husbands et al., 2001; Castro et al., 2003; Squires et al., 2004; Trujillo et al., 
2007; Zhang et al., 2009; Barsanti et al., 2010; Herraiz et al., 2010; Yadav and Nandi, 
2014). The apparent and wide array of differences in mechanisms of action may be 
attributed to the differential structures as well as the target of cancer cells.  
 
1.1.9 Evaluating potential anticancer activity of β-carboline  
 
All these reports have piqued the current interest in investigating anticancer effects of β-
carboline, and justified the purpose of the present study. Brief introductions on the 
methods undertaken in this study are mentioned in the following sections.  
 
1.1.9(a) Cytotoxic activity using 3-(4,5-Dimethylthiazol-2-yl)-2,5  
              diphenyltetrazolium bromide (MTT) assay 
 
In this study, MTT assay was used to evaluate cell viability in cancer cells as a primary 
and secondary screenings, and it has also been adapted differently to investigate other 
parameters. MTT assay evaluates viable cells through the estimation of their metabolic 
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activity, and its widely use has been well recognized worldwide. In principle, the viable 
cells contain mitochondrial dehydrogenase, which acts to cleave yellow dye of MTT and 
as a result of that, measurable purple formazan is formed. Since the purple formazan is 
impermeable to cell membranes, it ends up accumulating in viable cells. This formazan 
production is a good measurement for evaluating cell growth as it is directly 
proportional to cell viability and inversely proportional to cytotoxicity (Butler, 2004). 
 
The use of MTT has become the gold standard in academic labs as evidenced by 
thousands of published articles, not just for its versatility, but also because it has 
adequate amount of simplicity, accuracy and reliability as a method to count 
metabolically active cells (Mossmann, 1983; Denizot and Lang, 1986; Freimoser et al., 
1999; Aziz, 2006; Riss et al., 2016). In addition, MTT poses several advantages over 
other assays as it is cost- and time-saving, works equally well for adherent and 
suspension cells and adaptable for high throughput of larger number of 
compounds/samples, which makes it suitable for primary screening (Pieters et al., 1988; 
Freimoser et al., 1999; Weyermann et al., 2005; Aziz, 2006). Moreover, the National 
Cancer Institute (NCI) has recommended the use of MTT assay as part of its in vitro 
anticancer drug discovery screen (Boyd, 1997). MTT assay has also been used in 
numerous cancer studies which utilized anticancer drugs to evaluate cell growth 
inhibitory effect (Istiaji et al., 2010; Lüpertz et al., 2010; Sharifi et al., 2015). In fact, 
based on the recommendations from an international workshop organized by the 
Interagency Coordinating Committee on the Validation of Alternative Methods 
(ICCVAM), National Toxicology Program (NTP) and Interagency Center for the 
Evaluation of Alternative Toxicological Methods (ICEATM), MTT assay was one of the 
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listed methods used for measurement endpoints for basal cytotoxicity (National 
Toxicology Program, 2001). Thus, MTT seemed to be the best selection to study 
viability of cells in this study. 
 
 
1.1.9(b) Acridine orange and ethidium bromide (AO/EB) fluorescence assay  
 
Apoptosis, also known as programmed cell death, is a well-controlled and tightly-
regulated physiological process which results in self-destruction of cells (Baskic´ et al., 
2006). It is a necessity for the normal development, homeostasis and function of the 
immune system as well as a response to cellular insults and oncogenesis (Golstein et al., 
1991; Cohen et al., 1992; Pradelli et al., 2010). Apoptosis is characterized by a sequence 
of specific morphological changes in preparation for cell death. It begins with the 
condensation of the cytoplasm and nuclear chromatin, followed by membrane blebbing 
and breakage of cells into apoptotic bodies, which still contain various cytoplasmic 
organelles and nuclear fragments. Next, phagocytic cells and macrophages which are 
nearby act to rapidly engulf these apoptotic bodies, and finally digest them in their 
lysosomes (Golstein, 1998; Van Herreweghe et al., 2010). The clearance system is so 
effective that little cell death is apparent (Golstein, 1998).  
 
On the other hand, there is another form of unfavorable cell death called as 
necrosis, and also termed as accidental cell death. Known as the alternative and toxic 
version to apoptotic cell death, necrosis causes cell to become a passive victim of cell 
death in a mode of death that is independent of energy. The process of necrosis is 
degradative, which leads to mitochondria swelling and rupture of plasma membrane. As 
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a result of that, inflammatory cellular contents are released to the surrounding area of the 
cell, leading to the presentation of self-antigens in an immunogenic form and ultimately 
causing tissue damage due to autoimmunity (Majno and Joris, 1995; Levin et al., 1999; 
Nagata et al., 2010).   
 
The distinction between these two types of cell death is essential to recognize the 
possible physiological or pathological effects which are caused by apoptosis and 
necrosis respectively. Hence reliable methods for detecting cell death and differentiating 
between apoptosis and necrosis are most vital. In this study, microscopic examination of 
AO/EB fluorescence staining of cells was used as it was deemed most suitable since it 
enables the performance of high-quality studies of cell morphology, nuclear and 
chromatin disintegration. Though the use of dyes AO and EB, this assay is capable of 
distinguishing viable and non-viable cells based on membrane integrity, giving this 
assay the ability to distinguish viable, early or late apoptotic and necrotic cells in a rapid 
and objective manner (Ashush et al., 2000; Baskic´ et al., 2006).  
 
1.1.9(c) Measuring the levels of caspase-3 and -7  
 
The intracellular machinery responsible for apoptosis seems to be similar in all 
mammalian cells. This machinery depends on an evolutionary conserved family of 
proteases that have a cysteine at their active site and cleave their target proteins at 
specific aspartic acids, and they are called caspases (Liu et al., 2005). Caspases play 
essential roles as apoptosis initiator and executor of mammalian cells (Lamkanfi et al., 
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2002). Apoptosis-inducing stimuli such as chemotherapy drugs induce apoptosis through 
the caspase-mediated pathway (Hensley et al., 2013). 
 
Known as the heart of the apoptotic machinery, caspases typically signal in a 
two-step cascade, beginning with recruitment of ‗initiator caspases‘ with large pro-
domains (such as caspase-1, -8, -9, -10) forming into large protein complexes in which 
they undergo proximity-induced autoactivation. From here, they act to specifically free 
‗executioner caspases‘ (caspase-3, -6, -7) of their short inhibitory prodomain and 
allowing them to cleave a large set of cellular substrates (Stennicke et al., 1998; Slee et 
al., 1999; Boatright et al., 2003). This amplifying proteolytic cascade of caspase 
activation is followed by degradation of cellular components, resulting in caspase-
dependent apoptosis (Rathmell and Thompson, 1999; Igney and Krammer, 2002; 
Degterev and Yuan, 2008).  
 
There are two classical pathways of apoptosis, which are the intrinsic 
mitochondrial pathway and the extrinsic death receptor pathway. Looking at Figure 1.4, 
the intrinsic pathway is regulated by B-cell lymphoma 2 (BCL-2) family members while 
the extrinsic pathway is regulated by FAS- and tumour necrosis factor receptor (TNFR)-
associated death domains. While each pathway is operated by multiple activation and 
inhibition of different types of proteins, both pathways eventually converge at the 
activation of the effector caspases (caspase 3, caspase 7 and caspase 6) to induce 
apoptosis (Li-Weber, 2013; Czabotar et al., 2014). Once activated, these executioner 
caspases are responsible for the proteolytic cleavage of a broad spectrum of cellular 
targets, leading ultimately to the disassembly of the cell (Liu et al. 2005; Li-Weber, 
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2013). Since caspase-3 and -7 are known to be major executioner caspases and protein 
markers for apoptosis, their upregulations were evaluated in this study to understand the 
underlying pathway of apoptosis (Walsh et al., 2008). 
 
To assess the levels of caspase-3 and -7, Caspase-Glo® 3/7 of Promega was 
utilized. Caspase-Glo® 3/7 assay is a homogeneous, luminescent assay that provides a 
luminogenic caspase-3/7 substrate, which contains the tetrapeptide sequence DEVD, in a 
reagent optimized for caspase activity, luciferase activity and cell lysis. Following the 
action of cleavage by caspase-3 and -7 as depicted in Figure 1.5, a substrate for 
thermostable luciferase (aminoluciferin) (Ultra-Glo™ Recombinant Luciferase) is 
released, resulting in the luciferase reaction and generating  light or a stable ―glow-type‖ 
luminescent signal, thus improving performance across a wide range of assay conditions 
(Promega, 2015). This assay is highly advantageous as it is a simple and robust assay 
which is able to provide rapid results that are highly selective for caspase-3 and -7 
Bayascas et al., 2002; Promega, 2015). In addition, this flexible assay has a greater 
sensitivity than other fluorescence-based assays because it avoids interference from 
fluorescence signals from test compounds, providing excellent signal-to-noise ratios and 
allowing the use of fewer cells in the study of apoptosis. This assay also enables the use 
of cultures of adherent or suspension cells, and its multiwell-plate format makes it ideal 
for automated high-throughput screening of caspase activity or apoptosis (Promega, 
2015).  
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Figure 1.4. The intrinsic mitochondrial- and extrinsic death receptor-mediated pathways 
to apoptosis (Source: Czabotar et al., 2014). 
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Figure 1.5. Caspase-3/7 cleavage of the luminogenic substrate containing the DEVD 
sequence, thereby releasing a substrate for luciferase (aminoluciferin) and resulting in 
the luciferase reaction and the production of light (Source: Promega, 2015).  
 
 
1.1.9(d) Flow cytometry 
 
The stages of the cell cycle are divided into two major phases which are interphase 
(consist of G1, S, G2) and mitotic (M) phase (Figure 1.6). During interphase, cell growth 
and DNA duplication occur, while during the M phase, cell separates its DNA into two 
sets, followed by division of its cytoplasm, and forming two new daughter cells. 
Different stages of the cell cycle are characterized by the different amounts of DNA that 
the cell nuclei contain. During the G1 phase, cells maintain diploidy (DNA content 
characteristic of two complete sets of chromosomes, 2N) as they undergo RNA and 
protein synthesis to prepare for DNA synthesis. Subsequently, DNA synthesis and 
replication occur in the S phase, where DNA contents are intermediary between G1 and 
G2 (2N to 4N DNA content). During the G2 phase, in preparation for the M phase, more 
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RNA and protein synthesis occur, and therefore DNA content is doubled and defined as 
G2 tetraploid (4N DNA content). At this phase, based on DNA content alone, M phase is 
indistinguishable from the G2 phase. In the process of mitosis, after the split of cell into 
two 2N daughter cells, these new cells either continue to enter another cycle or go into a 
resting phase defined as G0. Based on DNA content, this phase is indistinguishable from 
G1 phase. Collectively, the replication cycle in flow cytometry is described by G0/G1, S, 
and G2/M phases (Wang et al., 2011).  
 
 
                      Figure 1.6. The stages of cell cycle (Source: Wang et al., 2017). 
 
Flow cytometry can measure DNA content of cells, which reveals not only the 
information on cell position in the cell cycle but also the ploidy and DNA content of a 
given cell population (Pozarowski and Darzynkiewicz, 2004; Wang et al., 2011).  
 
